NKARTA THERAPEUTICS
Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases an... d pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
NKARTA THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2015-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.nkartatx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
125 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics Apache
Similar Organizations
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
SR One
SR One investment in Series B - Nkarta Therapeutics
Amgen Ventures
Amgen Ventures investment in Series B - Nkarta Therapeutics
Deerfield
Deerfield investment in Series B - Nkarta Therapeutics
Life Sciences Partners
Life Sciences Partners investment in Series B - Nkarta Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series B - Nkarta Therapeutics
Novo Holdings
Novo Holdings investment in Series B - Nkarta Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - Nkarta Therapeutics
Logos Capital
Logos Capital investment in Series B - Nkarta Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Nkarta Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series A - Nkarta Therapeutics
Official Site Inspections
http://www.nkartatx.com Semrush global rank: 2.42 M Semrush visits lastest month: 7.47 K
- Host name: 238.41.180.107.host.secureserver.net
- IP address: 107.180.41.238
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
